EDITORIAL SECTION

KNOWLEDGE BANK

  • Techno Trends

    Lilly’s Jaypirca Gains FDA Approval for First-Line CLL/SLL Treatment

    Eli Lilly and Company has received approval from the US Food and Drug Administration FDA for an additional indication for Jaypirca pirtobrutinib in adults with previously untreated chronic lymphocytic leukaemia CLL or small lymphocytic lymphoma SLL without a known p deletion The approval enables Jaypirca to be used as a firstline treatment

TOP ARTICLES

  • 1

    How to Successfully Enter the American Pharma Market?

    Kate Williamson

    Entering the North American pharmaceutical market demands a comprehensive strategy. Understanding FDA regulations, conducting thorough market analysis, building strategic partnerships, adapting to hea...

press releasesRead more...

CareValidate Launches First Same-Day Prescription Delivery for Telehealth Brands, Starting with GLP-1 Treatments in Houston

CareValidate the compliance and clinical infrastructure behind some of the fastestgrowing telehealth brands in the country is launching sameday prescription delivery in Houston Telehealth businesses on the CareValidate platform can now offer eligible patients home delivery within hours instead of wa...

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

Emergent BioSolutions Inc announced that it has received a modification exercising an option period under its existing delivery order valued at up to million to supply BioThrax Anthrax Vaccine Adsorbed to the US Department of War DoW The first delivery which is valued at approximately

Evommune Enters into Agreement to In-License EVO570, a Potential Best-in-Class Oral VAV1 Molecular Glue Degrader, from Hinova Pharmaceuticals

Evommune Inc a clinicalstage biotechnology company developing therapies for chronic inflammatory diseases and Hinova Pharmaceuticals Inc SSE today announced an exclusive license agreement granting Evommune worldwide rights outside of Greater China

Global Pharmaceutical Company Commits to a Dual-Site Deal with AGC Biologics Exceeding €0.5 Billion

AGC Biologics has expanded its existing longterm manufacturing agreement with a global pharmaceutical company adding a second supply node at the CDMOs Copenhagen facility The expansion which builds on the existing agreement anchored at AGC Biologics

09 - 11

Nov 2026

11th Microbiome Movement USA Summit

The Colonnade Hotel, Boston, M...

10 - 11

Nov 2026

Extractables & Leachables Europe

Parkhotel Schӧnbrunn, Vienna,...

10 - 12

Nov 2026

Lab Asset & Facility Management Summit

The Westin Boston Seaport Dist...

11 - 13

Nov 2026

Frontiers in Cancer Science 2026

One Farrer Hotel,1 Farrer Park...

11 - 12

Nov 2026

24 - 25

Nov 2026

24 - 27

Nov 2026

Pharmtech & Ingredients 2026

Crocus Expo, Pavilion 2, Mosco...

LATEST NEWSRead more...

PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product

PharmAla Biotech Holdings Inc a biotechnology company focused on the research development and manufacturing of MDXXclass molecules including its proprietary LaNeo MDMA announces that it has signed an agreement with Corealis Pharma Inc Corealis a GMPcompliant contract development

Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance

Thermo Fisher Scientific the world leader in serving science today introduces the Thermo Scientific AmpSure Universal SYBR Green and Probe Master Mixes Designed for everyday applications the mixes support reliable reproducible quantitative PCR qPCR performance and offer researchers a valuepriced opt...

Polaris Rx Selected by Bristol Myers Squibb to Dispense ZENBEXUS™ (iberdomide), the First FDA-Approved CELMoD Therapy for Multiple Myeloma

Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS iberdomide the first cereblon E ligase modulator CELMoD therapy approved by the US Food and Drug Administration FDA ZENBEXUS is approved in combination with daratumumab

Moleculent Introduces Glimt, the First Automated Instrument for Functional Profiling of Cell-Cell Interactions in Human Tissue

Moleculent AB the life sciences technology company pioneering functional profiling today announced Glimt an automated platform that detects cellcell interactions directly in formalinfixed paraffinembedded FFPE tissue The Glimt platform is now available to selected academic

Rhythm Pharmaceuticals and LG Chem Enter into Amendment to Bivamelagon Exclusive License Agreement

Rhythm Pharmaceuticals Inc announced an amendment to the global exclusive license agreement with LG Chem Ltd for bivamelagon an investigational oral smallmolecule melanocortin receptor MCR agonist The Company also announced a fiveyear term loan facility led by KKR

SCIEX Launches LeadScape Compatible with SCIEX OS Software to Accelerate High-Throughput Drug Candidate Evaluation

SCIEX a Danaher company and leader in life science analytical technologies today announced the launch of LeadScape compatible with SCIEX OS software a new highthroughput workflow solution that accelerates drug candidate evaluation Developed by Sound Analytics the software